Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa PD-L1 IO103 vaccine in basal cell carcinoma
2018-002605-62Phase 2Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Jul 2018
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IO103 + Montanide in basal cell carcinoma (BCC), sponsored by Herlev & Gentofte Hospital. Primary endpoint: Disease control rate after 6 IO103 treatments. Started Jul 2018; status: completed.
02
Drugs
IO103 + Montanide
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2018-002605-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002605-62.